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Abstract
Automated technologies have revolutionised the monitoring of coagulation disorders in the
central hospital laboratory setting, allowing for high throughput testing, improved accuracy
and precision, accompanied by a marked reduction in human error. However, they still
require trained operators and sample transportation. With the advent of point of care (POC)
testing, the working principle of traditional coagulometers was used as the foundation for the
development of miniaturised devices. A number of POC coagulation devices have been
commercially available for many years now, allowing the patient to assume more control
over the management of their own medication, e.g. warfarin. While POC devices for
measuring anticoagulation have relied principally on clotting time tests, novel platelet
function tests, and factor-specific assays based on enzymatic or immunoassay principles are
becoming available, driven by the emergence of new anticoagulant drugs, in addition to the
inability of clotting tests to accurately detect many thrombotic disorders. This review
highlights recent progress in the development of POC coagulation monitoring technologies
and examines their future potential in clinical diagnostics.
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1. The development of central laboratory coagulation testing

The monitoring of bleeding disorders has been in existence for around 3000 years with the
first bleeding time test described by the Chinese emperor Huang Ti, as the length of time that
blood flows from the skin after rupture. The bleeding time was also described by Sydenham
at the turn of the 17th century, but it was not until the 1900s when disorders of the clotting
system were detected using bleeding time at the bedside [1].

While comparatively more sophisticated in their mode of operation, many coagulation tests
still use the same principles since their discovery in the early 19th century, where it was found
that blood coming into contact with glass containers or various biological tissues such as
placenta accelerated its clotting [1,2]. The development of the understanding of the
coagulation cascade and the interaction of various factors led to the development of the first
clotting time tests (Fig. 1). These tests now principally include the Prothrombin Time (PT)
test, which measures the tissue factor-induced clotting time of plasma [3], the activated
Partial Thromboplastin Time (aPTT), one of the most frequently requested screening tests for
monitoring unfractionated heparin (UFH) therapy [4, 5], the Activated Clotting Time (ACT),
currently used to monitor anticoagulation in patients undergoing cardiopulmonary bypass
(CPB) and are receiving high doses of UFH [5], and the Thrombin Time test (TT), a simple
assay measuring the conversion rate of fibrinogen to insoluble fibrin after the addition of
thrombin to plasma [6]. Changes from the normal clotting times of these assays may result
from changes in active coagulation factor concentrations due to genetic factors, disease or
injury, or through the administration of anticoagulant drugs.

Initially, assay methods were based on the visual detection of a clot, either through
observation of fibrin strands, or detection of bulk changes in viscosity [2,3,7] (Fig. 2). The
level of automation involved was typically around controlling the mixing and interaction of
the sample with the clotting reagents or surface contact with glass. Progressively, visual
detection of clot formation was replaced by optical detection technologies, using
turbidimetric [1] and nephelometric [8] techniques in which the change in optical density of
the sample resulted from the formation of the fibrin network. Mechanical detection also
replaced visual detection in which the change in viscosity was detected, for instance by the
cessation of the movement of a steel ball in the rotating sample tube which could be detected
optically [9]. This level of automation led to many advantages over manual testing, such as
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high volume testing, better reproducibility due to strict quality control programs, increased
user flexibility, and cost reductions.

Coagulation instruments based on optical detection of clot formation could also be made
compatible with the need for other assays applicable to haemostasis. This was particularly
useful for the measurement of the activity of coagulation factors. These factors are typically
serine protease enzymes that transform an inactive zymogen into its active form. The
development of chromogenic substrates that, when cleaved would release a chromophore
now allowed enzymatic factor assays to be performed alongside traditional coagulation tests
on a single instrument platform [10]. Other systems developed modified latex agglutination
assays to perform immunoassays, again exploiting principles such as turbidimetry [11,12].
This has been further refined through the use of particle proximity assays in which the close
proximity of two particles due to a binding interaction, results in a signal from one of the
particles. For example, in the Luminescent Oxygen Channelling Immunoassay (LOCI) the
photoactivated formation of short-lived singlet oxygen on one particle is then capable of
inducing chemiluminescence on a neighbouring particle when bound together via an
antibody-antigen interaction [13]. A number of popular commercial central hospital
coagulometers and their characteristics are listed in Table 1.

2. The development of point of care coagulation testing

The need for point of care (POC) coagulation technologies became necessary as centralized
laboratories became increasingly unable to provide results in the time frames required to
allow rapid turnaround which would allow timely intervention of anticoagulant therapy [14].
This was equally so for inpatients requiring dosage adjustment during emergency procedures
or for outpatients to allow dosage adjustment before leaving the clinic. Such improvements
were thus necessary to improve patient satisfaction and improve clinical outcome [5].

While the initial costs of POC testing may be greater, the wider patient, economic, and
societal benefits offered by the implementation of such programs cannot be ignored. In a
recent review [15], the effects of POC coagulation testing on the rate of perioperative
transfusion of allogenic blood products, the frequency of hemostatic treatment, and the
clinical outcome were assessed. While POC treatment is limited, the implementation of such
programs may potentially reduce rates of transfusion and lower costs associated with
4

hemotherapy. Lee-Lewandrowski et al. [16] looked at the impact of a POC testing program in
a large academic medical centre where over 500,000 tests are performed annually, ranging
from glucose and creatinine testing, to ACT and D-dimer analysis. According to their report,
the majority of POC tests was actually performed to improve clinical operations and to aid in
capacity management of the hospital facilities, and not out of medical necessity. Thus,
improvements were observed in clinical operations rather than clinical outcomes. A similar
trend was observed with studies for cardiac markers in emergency department settings, where
the length of stay for patients was significantly reduced but with little improvement in clinical
outcome [17]. Nichols et al. [18] monitored the clinical outcomes of POC testing in the
cardiology setting, and while rapid results were achieved, the impact on patient care was not
obvious.

Goodnough & Hill [19] have highlighted the need for POC coagulation testing in clinical
settings including liver transplantation, cardiothoracic surgery, and trauma because of the
high risk of hemorrhage and the resulting requirements for blood component support. Other
research has identified that POC testing in the form of platelet count, PT, aPTT and
fibrinogen concentration has resulted in reduced blood loss, shorter surgical times, and
reduced transfusion requirements [20,21]. Asimos et al. [22] conducted a study on trauma
patients and determined that taking POC blood measurements such as haemoglobin resulted
in reduced morbidity. While clinical outcomes reporting morbidity and mortality indices will
give a greater indication of the effectiveness of various POC assays, this data will take a long
time to accumulate.

2.1. POC clotting time tests

Given the importance of clotting time tests such as PT, aPTT and ACT in the central
laboratory setting, these were, unsurprisingly, the first tests to undergo significant
development and conversion to POC type platforms [18]. One major driver was the need to
have rapid information in the operating theatre on blood coagulation status. The first POC
instruments were thus simple, bench top versions of earlier coagulometers, often employing
the same principles. For example, the Hemochron® Response system (ITC, USA) employed
the Hall effect in which the clotting of the blood sample caused a small magnet to rotate with
the sample in the tube, and so changing the magnetic flux of an external electromagnet [23]
(Fig. 3a). This is still widely used to perform ACT measurements for high dose heparin
5

anticoagulation in major surgeries. The device was gradually equipped with two sample tubes
due to the fact that full anticoagulation requires several hundred seconds of measurement
time. Thus, assays could be performed alternately to ensure a timely result. The Actalyke®
XL and Actalyke® Mini II (Helena Laboratories Point of care, USA) use a related principle
of operation in which two magnetic sensors are used to detect the movement of a magnet
inserted in the ACT tubes [24]. These two sensors, one at 0º and the other at 90º,
independently sense the magnet in the ACT tube. As the clot begins to form, it displaces the
magnet in the test tube. When the magnet reaches a fixed distance between the two detectors
(i.e. approximately 46º away from detector at 0º), the system returns the ACT clot time [25].

Until the 1950s, anticoagulant treatment could only be given parenterally in the form of
heparin, which limited its use to the hospital setting [26]. The introduction of warfarin as an
oral anticoagulant allowed the continuous treatment of those at risk of venous
thromboembolism and is still one of the top 40 most prescribed drugs in the USA [27].
However, coumarin has quite unpredictable dose-response characteristics and has a relatively
narrow therapeutic window, leaving patients at an elevated risk of bleeding or clotting [28].
This resulted in a major drive to develop devices that could be used in primary care settings
such as clinics, by GP surgeries, or even by the patient themselves to allow the more precise
control and adjustment of dosage. In the early 1990s a POC device for monitoring warfarin
treatment was introduced by Boehringer Mannheim (now part of Roche Diagnostics) called
the CoaguChek®, which was capable of performing PT measurements. The device used a
simple, disposable microfluidic strip in which a whole blood sample taken by fingerstick was
combined with a thromboplastin reagent in the presence of small iron filings [29]. These
filings could be induced to move by the application of an electromagnetic field and this
movement was then detected optically (Fig. 3b). The cessation of movement as a result of
coagulation can be detected as the clotting time. This device was also capable of measuring
PT using the International Normalized Ratio (INR) which allowed the standardization of PT
assays based on World Health Organisation reagents and assay methodologies [30]. Thus, an
INR from one device could be reliably compared to the value determined on another. Before
the introduction of INR, all PT clotting times were specific for the reagents and test device
used. This is still the case, however, for other coagulation tests such as aPTT, for which no
international standard has been established.
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Other POC devices for PT/INR have persisted with the mechanical approach to clot
formation. For instance, The Coag-Sense™ PT/INR monitoring system (CoaguSense Inc.,
USA) is based on a test strip with a rotating, spoked wheel that draws the sample into the
reaction well. The spokes rotate across the path of an infrared light beam and mixes the liquid
sample with recombinant rabbit thromboplastin which is dried in the reaction chamber. When
the sample clots, the spokes simply lift the fibrin clot from the reaction well and the
interruption of the light beam is measured by an optical detector. The PT is reported as the
time between the introduction of blood onto the test strip and blockage of the light beam in
seconds [31]. The manufacturer states that as it is a direct mechanical measurement, results
are not affected by low hematocrit levels or by the concentration of blood constituents,
resulting in more precise and reliable results [32]. While the assay only requires 10 µl of
sample, the instrument itself is more bench top than hand-held or portable.

While there are now numerous devices available for self-testing of PT/INR in association
with warfarin therapy, other coagulation tests such as aPTT and ACT have remained for
professional use only. There are several devices that can perform panels of clotting time
measurements in a small, portable device, with accompanying reductions in required sample
volumes, materials and reagent costs through the development of disposable polymer chiptype technologies. For example, in the Hemochron® Signature, 15 µl of whole or citrated
blood is added to a polymer microfluidic test cartridge containing coagulation reagents (Fig.
3c). The sample and reagents are mixed with the aid of pumps within the instrument. This
mixing homogenises the sample and reagent and ensures even clotting of the sample. The
mixture is then moved back and forward within the channel which is monitored by a series of
LEDs. Cessation of movement due to clotting is again detected optically. These devices
which again rely on cessation of movement due to clot formation can typically form a panel
of assays for PT/INR, aPTT and ACT.

2.2. POC methods and devices based on thrombin activity

As was discussed in the context of central hospital laboratory haematology, chromogenic
assays have been used to measure the enzymatic activity of specific clotting factors through
the development of artificial, cleavable peptide substrates specific for particular factors. It
should be noted that assays based on clotting time such as aPTT, PT and ACT are essentially
functional measures of thrombin formation and its inhibition in the presence of anticoagulants
7

such as warfarin and heparin. Thus, an analogy can be drawn between assays based on the
measurement of fibrin formation and assays based directly on the measurement of thrombin
activity via the use of appropriate peptide substrates such as in chromogenic assays.

The electrochemical behaviour of blood has been studied since 1928 [33,34]. Electrochemical
detection involves the use of a working and a reference electrode, whereby a constant
potential is applied to the working electrode leading to an oxidation-reduction reaction that
can be quantified as a recordable electric current [35,36]. Electrochemical sensors have found
widespread use in the development of POC and self-test devices, as exemplified by the
development of glucose test strips as they are simple to interface with electronic instruments
and reduce device costs. Devices such as the CoaguChek® XS (Roche Diagnostics) and the iSTAT® (Abbott Diagnostics) have both employed electrogenic substrates which result in the
formation of an electrochemically detectable cleavage product which is proportional to
thrombin activity. These devices then return a clotting time rather than a measure of thrombin
activity to allow comparisons with standard clotting tests. However, while the i-STAT® is
targeted at professional use and can perform PT/INR and ACT, the CoaguChek® is targeted
at the self-test market for PT/INR (Fig. 4a).

INR values of 52 patients receiving oral warfarin were measured using the i-STAT® PT/INR
and the CoaguChek® XS Plus and compared with those obtained using the reference
laboratory instrument from Diagnostica-Stago (France). Considering the results obtained,
INR measurements generated using the CoaguChek® XS Plus correlated better with the
Stago system than the results generated using the i-STAT® PT/INR [37]. However in a more
recent study, Challen et al. [38] evaluated the impact that close monitoring using the iSTAT® had on outcomes of patients on anticoagulant treatment. Their positive results
showed that implementation of the i-STAT® POC machine in a pharmacist-managed
anticoagulation clinic increased the proportion of time within therapeutic INR range by 9.9%.
In addition, safety, adherence and cost were improved, indicating potential for
implementation on a larger scale in the future.

As well as devices that use electrochemical analogies to available chromogenic tests such as
the iSTAT® and the CoaguChek® XS, some have attempted other direct means of
electrochemical measurement. In some cases, the change in the steady state current is related
to a change in sample viscosity [39] and in others, the cleavage of an amperogenic substrate
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leads to an electric current flow which can, for example, relate to thrombin generation [36].
One of the advantages of electrochemical detection is that sample colour/turbidity and the
presence of clots or platelets do not affect the measurement [36].

The Alere (formerly HemoSense) INRatio® is a disposable polymer strip with screen printed
silver paste electrodes in combination with PT assay reagents [40]. Application of the whole
blood to the strip and activation of coagulation is monitored using electrochemical
impedance. This technique is sensitive to a number of physical and chemical characteristics
of the sample. Electrochemical impedance measures both capacitive and resistive
characteristics of the material in contact with the electrode. Blood is a complex mixture of
ionic species, insulating biomolecules and interfaces such as membranes which all contribute
to its electrochemical impedance properties. In addition, these characteristics also change
over time due to the movement of cellular species, formation of the fibrin network and the
trapping of cells, platelets and plasma within this matrix. As a result, changes in the
resistance of the coagulating blood can be detected which can be related to the clotting time.
The INRatio® is also currently used for self-test measurement of PT/INR (Fig. 4b).

Most POC tests for measuring thrombin activity have been based on in vitro methods.
However, in vivo methods for thrombin measurement have the potential to yield further
information as to its role at the vascular level. Campbell et al. [41] employed laser scanning
confocal microscopy (LSCM) to observe in situ thrombin generation, where it has been seen
to form a fibrin network more rapidly, densely and in a manner more resistant to lysis than in
vitro. Such knowledge can be used to determine targets for anticoagulant therapy, which can
either prevent thrombosis or stabilize fibrin clots, thus preventing embolism. The role of
thrombin in atherosclerosis has also been studied using intracellular fluorescent probes of
thrombin activity used in combination with in vivo fluorescence imaging [42]. Other in vivo
studies of thrombin have employed microenzyme immunoassay to measure thrombinantithrombin complex (TATc) levels, and correlated these against images of atherosclerotic
plaques using non-invasive computed tomographic angiography [43]. Such studies have
indicated that in vivo thrombin generation is independently related to the occurrence and
severity of coronary artery disease.

9

2.3. Immunoassays for POC coagulation testing

While other assay types such as chromogenic and immunoassay were readily integrated into
laboratory-based coagulometers, development of such assays in the POC sector has been
principally through stand alone platforms for a number of critical analytes. One of the key
analytes is D-dimer which is used to diagnose thrombosis or disseminated intravascular
coagulation (DIC) [44]. D-dimer is formed as a result of the breakdown of a clot following
fibrinolysis and is typically measured using immunoassay. The Triage® system (Alere, USA)
uses a microfluidic cartridge with capillary structures to meter the volumes of blood used in
the assay, and a series of reaction areas in which the sample mixes with immobilised reagents
for defined time periods. Here, the D-dimer binds to a labelled antibody which is in turn
captured at a capture site downstream forming a coloured line. The Triage® is an example of
a lateral-flow type immunoassay converted to a polymer microfluidic platform. In a study on
a number of POC D-dimer assay platforms, Geersing et al. [45] showed that while there were
variations in their ease of use all platforms exhibited comparable accuracy.

While clotting factor deficiencies have traditionally been diagnosed using conventional
clotting assays, immunological tests are more suited to the study of hereditary thrombotic
states or predisposition such as protein C, protein S, antithrombin and tests for evidence of
DIC including fibrinogen degradation products (FDPs), fibrinogen, and D-dimers [46]. Most
POC devices use antibody-antigen binding technologies as they allow for assay specificity
and sensitivity and are versatile in the detection methodology that can be used such as
fluorescence, time resolved fluorescence or turbidimetry [47]. On the other hand,
immunoassays are often time consuming and depending on the specificity of the assay, the
antibodies of choice can be expensive. Sensors based on immunoassays often have difficulty
competing with traditional immunoassays which typically demonstrate greater sensitivity.
However, they do hold promise for testing where sensitivity can be sacrificed for improved
ease of use and faster time to result, such as in near-patient setting [48].

2.4. Resonant transducers

What is clear from the earlier discussion is that a large number of coagulation tests have
exploited the change in viscosity that results from clot formation. Initially, this was achieved
using slow, bulk methodologies. However, the tilt tube test introduced an important principle
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which has been further refined and applied to coagulation testing, which is the application of
an oscillatory force to the system. This was enhanced in other devices such as the
Hemochron® Signature in which the sample was pumped backwards and forwards to
enhance and detect clotting. In an extension of what is essentially a form of oscillatory
rheometry, other systems such as the Thromboelastograph® (TEG®, Hemonetics Corp.) and
ROTEM® (Tem International, GmbH) have used the application of an oscillating sheer force
to measure the resulting sheer stress in a time-dependent manner during coagulation [2,49].
These technologies have found favour particularly among anaesthesiologists as they provide
complex but detailed information on patient clotting status and fibrinolysis. For instance,
TEG® traces can show clotting times, rates of clot formation, and overall clot strength. These
parameters contain vital information as to levels of clotting factors, platelets, and fibrinogen
concentration. However, due their size and complexity, oscillatory rheometry has not
transitioned into wider POC application and acceptance.

Several miniaturized resonant transducer systems have been applied to blood coagulation
measurement. Devices such as the quartz crystal resonators are also sensitive to changes in
viscosity of a material in contact with its surface. These devices typically operate at high
frequencies (10-20 MHz) and their penetration depth into the sample is only on the order of
100-200 nm. They have been extensively investigated for their ability to monitor blood
coagulation. However, the cost of quartz crystal resonators makes it prohibitive as a single
use disposable device, while re-use is made challenging as biomaterials such as fibrin adhere
extremely well to the gold electrode surface and are very difficult to regenerate effectively.
Others are now employing alternative microresonators based on MEMS technologies. One
such system is the disposable SmartStrip® developed by Microvisk Technologies Ltd (UK)
[50]. Microvisk uses MEMS blood sensors on a disposable strip, which incorporates two
microcantilevers to measure changes in viscosity of the blood over time. One measures blood
thickness, while the other one detects background vibrations that are subtracted to provide a
better signal. The cantilevers are comprised of several layers of materials: plastic (two
polyamide strips), heaters and sensors (piezo-resistive element). The heater and the piezoresistive element are located between the two polyamide layers which have different
coefficients of expansion. With an increase in temperature, the cantilevers vibrate while the
piezoelectric generates a small current that indicates how much they flex. When a drop of
whole blood taken by a finger prick reacts with the dried thromboplastin stored on the strip,
the blood starts to coagulate. This change in viscosity is sensed by the cantilevers and
11

transmitted to the piezo-resistive layer indicating the coagulation endpoint [50–52]. These
devices can be mass-manufactured at low cost, which is an essential requirement for single
use disposability.

Table 2 summarizes the characteristics of 23 commercially available POC coagulation
analyzers [5,14,25,53,54,55].

2.5. POC tests for platelet function

With the increase in understanding of the role played by platelets in arterial thrombosis,
growing numbers of patients are being treated with platelet inhibitors (e.g., aspirin) and other
non-steroidal

anti-inflammatory drugs,

thienopyridine

derivatives

(e.g.

ticlodipine,

clopidogrel) and GP IIb/IIIa receptor antagonists (e.g. tirofiban, Abciximab) [54,56].
Treatment with these antiplatelet drugs has enhanced the need to monitor their effects in
order to avoid bleeding and thrombosis. Platelet testing was traditionally based on platelet
aggregometry. However, such tests do not represent physiological conditions [57,58]. Several
novel platelet function tests have been developed to assess platelet function and the impact of
antiplatelet therapies at the POC [5,25,53,57] (Table 3). One of these, the VerifyNow®
(Accumetrics, USA) is essentially a form of miniaturised light transmission aggregometry
performed in a disposable cartridge. The level of aggregation is sensitive to a number of
antiplatelet therapies [59]. However, such devices again do not fully take into consideration
the complex nature of platelets and their interactions with soluble clotting factors, surfaces
and each other [60], resulting in the lack of test standardization in the assessment of
antiplatelet therapy [54,61].

3. Future perspectives

While there have been many technological advances in coagulation testing in the last one
hundred years or so, many technologies are still measuring changes in bulk viscosity, or use
other relatively simple principles such as enzyme activity or particle aggregation. However,
the drive for POC has also driven technological solutions which can operate at the microscale
and many such innovations have been implemented in the available commercial technologies.
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While there is quite an array of devices for performing clotting time tests, there still remains
the need to improve and refine the way clotting end points are determined. Table 4 outlines a
selection of novel technologies from the research literature [36,62–68]. At present, the
clotting time is a relatively arbitrary point at which the burst in thrombin production leads to
an exponential rise in fibrin formation. It is this rapid change that is assigned as the clotting
time. However, the precise onset of this process is highly unpredictable. In a large, bulk
sample, initiation of coagulation processes may take place at different times and different
locations, leading to an inherent imprecision in the derived clotting time value. The ACT test
for example, has been shown to be highly variable for use in patients undergoing
cardiopulmonary bypass in instances of hypothermia and haemodilution, resulting in the
unreliable assessment of anticoagulation [69]. Dudek et al. [63] developed a microstructured
microfluidic device for performing an aPTT assay that analysed clot formation at the
microscopic level using a fluorescent fibrinogen label. They found that clotting time could be
determined by monitoring the distribution of clot formation using the fluorescence generated
from the incorporated labelled fibrin. This led to very precise measurement of clotting time,
as well as a much wider dynamic range for heparin measurement beyond the range typically
used in conjunction with aPTT and normally requiring ACT.

There is also a demand for novel POC assays for haemostasis. Some of this relates to the fact
that many standard tests have not yet translated into POC formats such as routine tests for
thromboembolic complications that can detect factor V Leiden, lupus anticoagulant, protein
C, protein S, and AT deficiency [70]. There is also a gradual move away from traditional
anticoagulant drugs such as warfarin and heparin due to their unpredictable pharmacokinetic
properties. This presents two challenges for coagulation testing. The first is whether there
will be a continuing need to monitor the effects of these new drugs, given their much
improved and more predictable characteristics and, the second is how they can be tested if
this is necessary. Already, clinical guidelines of the monitoring of novel anticoagulant
therapies are demonstrating that while the requirement for testing may be reduced, it will still
be necessary for atypical patients such as pregnant women, children, under- and overweight
people and people with renal dysfunction. In addition, low molecular weight heparins cannot
be effectively monitored using current clotting time tests as these are predominantly based on
thrombin formation. Low molecular weight heparins have far less impact on thrombin, but
exert their control in the preceding step in the coagulation cascade where they primarily
inhibit Factor Xa activity. Thus, tests for Factor Xa at the point of care may become
13

increasingly important. A novel fluorogenic anti-FXa assay was developed for monitoring
low molecular weight heparins by Harris et al. [71]. The assay was further developed and
modified and the ability to measure the concentration of both unfractionated and low
molecular weight heparin anticoagulant drugs in plasma was demonstrated using a polymer
microfluidic device (unpublished data).

As with the emergence of the laboratory-based coagulometers, the ability to perform multiple
assay types on a single platform is also an increasing driver for POC devices. This means
that, where possible, the assays must share a common transduction mechanism. For example,
Aizawa et al. [72] developed an immunosensor for measuring fibrinogen and fibrindegradation products based on quartz crystal resonator employing a latex agglutination assay.
In the presence of fibrin degradation products and latex beads with immobilised antibodies,
agglutination at the surface of the quartz crystal brought about a measurable change in
resonant frequency. Such an assay could share a common microresonator platform with clotbased assays using a commercially viable MEMS-based technology.

While attempts to improve POC testing are currently focussed on the development of lowcost miniaturised devices [73], Giljohann and Mirkin [74] suggested that new materials such
as nanostructures, present attractive properties for the development of miniaturized
biodevices such as controllable size-dependent properties, adaptable chemical composition,
and chemically and physically robust structures. Polyvalent nanoparticles, carbon nanotubes,
and silicon nanowires are all materials that can allow for the easy translation of a change in
electrical conductance due to target binding, into a spectroscopic or electrical signal.
Nanoshells and noble-metal nanoparticles can be modified to recognise biomolecules so that
they can detect proteins, elemental ions, and small molecules. Such strategies allow
adaptation for many analyte types and due to the properties of nanostructures, they can be
easily manipulated providing excellent versatility and increased sensitivity. Label-free
technologies such as the microsphere resonator biosensor for thrombin measurement as
developed by Zhu et al. [75] highlight another area of biosensor development that will allow
for high sensitivity and selectivity with a wide range of biomolecules.
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4. Conclusions

In the one hundred years since the first clotting time tests were proposed, the development of
coagulation assay technology has progressed significantly to a point where it now allows
individuals to assess their own clotting status in the comfort of their own homes. The range
and the quality of the tests available has also increased significantly, allowing various
measures of clotting time, platelet function, factor activity, and concentration. These tests
have progressed alongside an increased understanding of the processes involved in
haemostasis and the development of anticoagulant drug therapies. Many of these tests are still
only relevant to professional use applications. Only in the case of PT/INR has coagulation
testing emerged as a consumer diagnostic product. Nonetheless, many POC platforms now
exist to facilitate the rapid and convenient measurement of clotting status in all clinical
scenarios including operating theatres, emergency rooms, in-patient and out-patient settings,
in the management of a wide range of conditions from the diagnosis of genetic coagulation
disorders, management of perioperative anticoagulation, in the treatment of thrombosis, and
for the prophylactic management of a wide range of thrombophilic conditions.

Many new technologies continue to be applied to enhance and refine the ability to perform
coagulation tests at the POC, primarily focussed on improved systems miniaturisation and
functional integration. While the technologies being used may be ingenious, the adoption of
such devices is not without many significant challenges which include the quality, robustness
and cost of the underlying technology, intellectual property issues, regulatory approval,
clinical acceptance, the economics of test usage and the ultimate market size. It is not
surprising then, that much technological development has been predominantly incremental in
nature. Coagulation testing is also under pressure from improvements in drug treatment that
claim to not require monitoring. While this may be partially true, the cost and rate of adoption
of new drugs, coupled to the complexities involved in managing patients with very specific
medical requirements will ensure that some amount of testing will remain for some time to
come and that new tests for new drugs may open up new testing opportunities. Certainly the
challenge of the management of the aging population may also see a continued demand for
devices suitable for out-patient and self-test use in an attempt to contain ever-increasing
healthcare spending. It is assumed that further technological development will continue to
make these cheaper, quicker and simpler to use.
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Tables

Table 1. Summary of selected laboratory coagulometers
Coagulometer
Automation Detection
Methodology
BCS® XP; Sysmex®
Full
Chromogenic
(Siemens Healthcare
Immunologic
Diagnostics, USA)
Photo-optical
Turbidimetric

Assay Menu
a2-Antiplasmin, Antithrombin, aPTT
TT,
Anti-Xa,
Fibrinogen
,
FII;FV;FVII;FVIII;FIX; ,FX; FXI;
FXII, FV-Leidin, LA, Plasminogen,
Protein C, PT, UFH, VWF

STA-R® series
(Diagnostica Stago,
France)

Full

Chromogenic
Immunologic
Mechanical

Antiplasmin, TAFI, Antithrombin,
aPTT
TT, UFH & LMWH, D-dimer,
Fibrin,
Fibrinogen,
LA,
Microparticles, Plasminogen, Protein
C & S, PT, VWF

Cascade® series
(Helena Laboratories,
USA)

Semi

Photo-optical

aPTT, ACT, PT, TT

ACL®
(Instrumentation
Laboratories, USA

Full

Chromogenic
Immunologic
Nephelometric
Photo-optical

Antithrombin,
APC-R,
aPTT
TT, Fibrinogen , D-dimer ,
Homocysteine,
LA,
FXIII,
Plasminogen, Protein C & S, PT, TT,
UFH & LMWH, VWF

KC® series
Destiny® series
(Tcoag, Ireland)

Semi; full

Mechanical
Chromogenic
Immunologic

aPTT, TT, Anti-Xa, Fibrinogen, PT

Table 2: Classification of commercially available coagulation POC devices based on their endpoint detection method
Type of detection
Device (Manufacturer)
Volume
Type of
Comments
(µl)
withdrawal
Hemochron® Signature +,
15
Fingerstick
Change in fluid oscillation
Signature Elite (ITC, USA)
Venipuncture
PT; ACT; aPTT – multiparametric tests
User friendly; quantitative; small sample volume;
handheld/portable; self contained waste channel

Optical

Cascade POC (Helena
Laboratories Point of care, USA)

35

Fingerstick
Venipuncture

Superparamagnetic oxide particles
PT; ACT; aPTT; Enox
Small sample volume; handheld/portable

ProTime® Microcoagulation
System (ITC, USA)

~25

Fingerstick

Blood is pumped through the channels
PT/INR
Stores patient data; onboard and external quality controls;
user friendly; handheld/portable

Coag-Sense™ PT/INR Monitoring
System (CoaguSense Inc., USA)

10

Fingerstick

Mechanical principle
PT/INR
Small sample volume; disposable strip; handheld/portable

GEM®PCL Plus (Instrumentation
Laboratory, USA)

~50

Fingerstick for
PT only

Change in fluid oscillation in a test channel
PT; ACT; aPTT
Handheld/portable; maintenance free; automated
measuring and mixing; customised programming options

microINR® (iLine Microsystems,
Spain)

3

Fingerstick

Microcapillary cessation of flow
PT/INR
Handheld/portable; user friendly; fully automatic

Electromechanical

Hepcon® HMS Plus™ Hemostasis 2,500Management System (Medtronic
3,000
Cardiac Surgery, USA)

Venipuncture

POC benchtop analyzer
Heparin dose; heparin protamine titration; ACT
Disposable cartridges; user friendly operation; storage
and data download options

Bio-AMD’s COAG (BioAlternative Medical Devices Ltd.,
UK)

-

Fingerstick

Optical-magnetic detection principle
PT/INR
Small simple volume; rapid results; USB connection for
data output; internal memory

ACT Plus™ System (Medtronic
Cardiac Surgery, USA)

400-800

Venipuncture

POC benchtop analyzer
Low and high range ACT
External data management software; unsuitable patient
self use

Hemochron® Response (ITC,
USA)

400 -2,000 Venipuncture
Fingerstick

Change in magnet position
PT; ACT; aPTT; TT; HiTT; heparin response; protamine
response
Gold standard testing technology; dual testing
capabilities; data management function; portable

Actalyke® XL (Helena
Laboratories Point of care, USA)

500

Venipuncture

Two-point soft-clot detection
ACT
Portable; dual well testing; reproducible; good data
handling

Actalyke® Mini II (Helena
Laboratories Point of care, USA)

500

Venipuncture

Two-point clot detection
ACT
Portable; sensitive; high visibility screen; inexpensive

Thrombotrack™ Select 2 (AxisShield, Norway)

15-100

Fingerstick
Venipuncture

2 measurement channels
PT; ACT; aPTT; Fibrinogen

Automatic start upon reagent addition; input of reagent
specific data
Thrombotrack™ Solo (AxisShield, Norway)

25-100

Fingerstick
Venipuncture

1 measurement channel
PT; ACT; aPTT; Fibrinogen
Software system controls reaction procedure

CoagLite® & CoagMax®
(Microvisk Technologies, UK)

5

Fingerstick
Venipuncture

MEMS technology
PT/INR
Handheld/portable ; in-built quality control checks; data
upload option via USB connection

i-STAT® (Abbott Point of care
Inc., USA)

17- 95

Fingerstick
Venipuncture

Electrogenic
PT/INR; ACT
Handheld/portable; rapid results; data upload to patient
chart; easy to use

INRatio®/INRatio2® PT INR
Monitor (Alere, USA)

~15

Fingerstick

Changes in impedance
PT/INR
Handheld/portable; large LCD; internal quality controls;
individually wrapped strips for storage at room
temperature; rapid results

CoaguChek® XS, CoaguChek®
XS Plus and XS Pro PT Test
System
(Roche Diagnostics, USA)

8

Fingerstick
Venipuncture

Amperometric detection
PT/INR
Handheld/portable; on board quality control; battery
powered; patient/operator identification

Electrochemical

Table 3. Current potential most commonly used POC devices for platelet function and antiplatelet
therapy analysis
Type of
Device (Manufacturer)
Sample type
Volume Platelet
detection
(µl)
Function
Device
VerifyNow® (Accumetrics, USA) *CWB
<1,000
Genuine POC
Optical

Electrical
impedance

Change in
pressure

Electromechanical

Impact® Cone and Plate(let)
Analyser (Matis Medical Inc.,
Belgium)

*CWB

~130

POC

Plateletworks® (Helena
Laboratories Point of care, USA)

*CWB

1,000

POC

Multiplate® (Roche Diagnostics,
Switzerland)

Hirudin or
heparin
anticoagulated
WB

300

POC

*CWB

800

POC

Heparin
anticoagulated
WB

small

POC

PFA-100® (Siemens Healthcare
Diagnostics,
Inc., USA)
TEG® Platelet Mapping™
System (Haemonetics, USA)

*CWB = Citrated Whole Blood

Table 4: Novel research methodologies and technologies in coagulation testing
New method
Characteristics
Sensitivity/accuracy

Application

Amperometric biosensor
for thrombin generation

Single use
Electrochemical sensor
10 µl sample

0.4-50 U/mL thrombin

Thrombin generation
Hemostatic function

[36]

Flow front position
and/or velocity-based
clotting time device

Disposable strip
Laminated polymeric chip
Capillary flow
Optical detection
LED illumination
3 µl sample
<1 minute results

Sample flow monitoring
correlates well with clotting time

PT/INR measurements
for warfarin monitoring

[62]

Lateral flow chip for
measuring fibrinogen
levels

Lateral flow
Zeonor
Visual measurement
15 µl sample
5 minute result

1-7g/L fibrinogen

Fibrinogen determination
Cardiovascular disease
risk

[63]

Quartz crystal
microbalance (QCM)
system for platelet
aggregation

Electrochemical transducer
Piezoelectric AT-cut α-quartz
Gold electrodes
180-225 µl

Frequency shifts correlate well
with % aggregation

Platelet aggregation
Cardiopulmonary bypass

[64]

Aptamer-based

Polymer chip

10 ng/mL thrombin

Thrombin measurement

[65]

Reference

microfluidic chip for
thrombin detection using
magnetic beads and
quantum dots

Pumping
Magnetic beads and quantum
dots
Fluorescence

Microfluidic device for
platelet aggregation
using micro-gradients in
flowing blood

Polydimethylsiloxane chip
200 µl sample
Epi-fluorescence imaging

Precise control over location of
forming aggregates

Platelet aggregation

[66]

Microstructured lateral
flow chip for fluorescent
detection of clot
formation

Lateral flow chip
Zeonor chip
25 µl sample
Fluorescence

0-2 U/mL heparin
Linearity (R2 = 0.99)

Heparin monitoring

[67]

Microfluidic impedance
cytometer for platelet
analysis

Pressure sensitive adhesive
chip with platinum electrodes
Dielectric focusing
Differential impedance
Spectroscopy
Frequencies of 280 kHz- 4
MHz
Syringe pumping

Distinguishes between resting
and active platelets
Distinguishes between red blood
cells and platelets

Platelet activation

[68]

Figure legends
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